Research and Markets: 2006 Market Research Available On Bristol-Myers Squibb Showcasing Its Current Growth Drivers

Research and Markets: 2006 Market Research Available On Bristol-Myers Squibb Showcasing Its Current Growth Drivers

Business Wire - December 21, 2006

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47514) has announced the addition of Bristol-Myers Squibb Prospects to 2010 from Espicom Business Intelligence to their offering.

Headquartered in New York, Bristol-Myers Squibb (BMS) is involved in the research and development of treatments for conditions such as heart disease, high blood pressure, stroke, diabetes, cancer, HIV/AIDS, depression, schizophrenia and pain. The company's research and development efforts are principally focused on Oncology, Affective (Psychiatric) Disorders and Metabolics.

Current Growth Drivers

Plavix (clopidogrel), a platelet aggregation inhibitor, is BMS' largest selling product and continues to make substantial year-on-year sales growth. The product benefits from co-development and co-commercialisation with sanofi-aventis in a number of markets worldwide. Since its first approval in 1997, Plavix has been prescribed for around 48 million patients.

Similarly, Avapro/Avalide (irbesartan), an angiotensin II receptor agonist indicated for the treatment of hypertension and diabetic neuropathy, was co-developed and co-marketed with sanofi-aventis in several markets and also has demonstrated steady market gains since its launch.

Abilify (aripiprazole), indicated for the treatment of schizophrenia and related conditions, is the company's flagship Affective Disorders product. The product was licensed from Otsuka, with whom BMS co-promotes Abilify in several markets, and has made strong sales increases since it became part of BMS' product portfolio.

Erbitux (cetuximab) was licensed from ImClone Systems to become BMS' first biological product. It is used in the treatments of various cancers and in March 2006, it became the first new treatment for squamous cell head and neck cancer in nearly three decades.

Reyataz (atazanavir), a potent azapeptide inhibitor of HIV protease, is the first once-daily protease inhibitor to be approved by the FDA. In 2005, it demonstrated the most significant growth of BMS' pharmaceutical products, with sales increasing by nearly 70 per cent from the previous year.

These pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Bristol-Myers Squibb is involved in the research and development of treatments for conditions such as heart disease, high blood pressure, stroke, diabetes, cancer, HIV/AIDS, depression, schizophrenia and pain. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Content Outline:

Principal Operating Results

Recent Product Approvals

Discontinued Products

UFT

R&D Strategy

Key R&D Projects

R&D Pipeline Overview

Discontinued R&D projects

Basulin

E2F Decoy

Pargluva

Ravuconazole (BMS-207147, ER-30346)

Sales Forecasts

Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT 27

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2005

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

APPENDIX 4 - INFRASTRUCTURE

APPENDIX 5 - KEY PHARMACEUTICAL

SUBSIDIARIES / JOINT VENTURES

APPENDIX 6 - PRODUCT INDEX

Index of Tables

Index of Charts

For more information visit

http://www.researchandmarkets.com/reports/c47514.

CONTACT: Research and Markets

Laura Wood

Fax: +353 1 4100 980

mailto:press@researchandmarkets.com

SOURCE: Research and Markets Ltd.
061221
BW061214

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .